Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04550663
Other study ID # 2020-172-01
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date September 25, 2020
Est. completion date March 25, 2023

Study information

Verified date September 2020
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact Baorui Liu, M.D
Phone +025-83106666 ext 61331
Email baoruiliu@nju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.


Description:

In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be asked to continue to undergo long-term gene safety follow-up.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date March 25, 2023
Est. primary completion date September 25, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age =18, male & female;

2. Patients with recurrent/refractory NKG2DL+ tumors diagnosis by pathological histology or cytology, focus on the inclusion of patients with hepatocellular carcinoma positive. (If recruit liver cancer patients, patients should with locally advanced or metastatic hepatocellular carcinoma (HCC), Barcelona clinic liver cancer (BCLC) staging system classification for B or C, for B, patients are not suitable for local treatment and/or surgery, or disease progression occurs after surgery and/or local treatment, or declined to surgery and/or local treatment);

3. Patients who fail first-line treatment or are unwilling to receive first-line treatment;

4. Disease progression occurred within 14 days before inclusion (RECIST criteria must be used as a basis for assessment of disease progression). According to RECIST V1.1, patients have at least one measurable lesion. Target lesions located within the field of previous therapeutic irradiation or within the area of local treatment (interventional or ablative treatment) are considered measurable if progress is confirmed;

5. The main organs function normally and meet the following requirements;

Blood routine examination shall be in accordance with (no blood transfusion within 14 days) :

1. HB=90g/L

2. ANC =1.5×10^9/L

3. PLT =75×10^9/L

serum biochemicals examination shall be in accordance with:

1. BIL <1.5 upper normal limit (ULN)

2. ALT and AST<2.5×ULN; In the case of liver metastasis, ALT and AST<5×ULN

3. Serum Cr=1×ULN, endogenous creatinine clearance=50ml/min(Cockcroft-Gault formula);

6. ECOG physical condition score: 0-1;

7. Expected survival time =3 months;

8. Cardiac function well before inclusion, no myocardial infarction attack occurred within half a year, and hypertension and other coronary heart disease were under control at present;

9. No other uncontrollable benign diseases such as lung, kidney, liver infection before enrollment;

10. Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 7 days of enrollment and voluntarily use an appropriate method of contraception during observation and within 8 weeks after the last administration; men should be surgically sterilized or agree to use an appropriate method of contraception during the observation period and within 8 weeks after the last administration;

11. Patients voluntarily participated in this trial and sign the informed consent form;

12. Patients with compliance and expected to follow up the efficacy and adverse reactions as required by the protocol;

13. CAR-T cells amplify successfully to the expected number.

Exclusion Criteria:

1. Pregnant or lactating women, pregnancy test positive by blood or urine within 48 hours before immune cell transplantation;

2. Patients who need to be treated with systemic steroid;

3. Under following treatment conditions currently:

1. during the other anti-tumor clinical observation period within 14 days before blood collection;

2. patient has not recovered from acute side effects of the previous treatment;

4. Receive radiotherapy within 4 weeks before enrollment;

5. Patients who received any other cell therapy before;

6. Transfection efficiency of lymphocytes of patients < 5% in feasibility assessment screening stage, or T cell amplification efficiency < 5 times;

7. Uncontrolled symptoms or other illnesses, including but not limited to infection, congestive heart failure, unstable angina, arrhythmia, psychosis;

8. Patients with severe acute allergic reactions, or the attending doctor believes there is an unpredictable risk;

9. Patients who have received other cell therapies;

10. Other serious conditions that may limit patient's participation in the study.

Study Design


Intervention

Drug:
KD-025 CAR-T cells
Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Locations

Country Name City State
China The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School KAEDI

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) Incidence of dose-limiting toxicities 90 days post infusion
Primary The occurrence of AEs and SAEs during the study treatment An adverse event is any undesirable experience associated with the use of a medical product in a patient 0 to 28 days post infusion
Secondary Objective remission rate(ORR) Imaging assessment of tumor remission 1 year post infusion
Secondary Progression free survival(PFS) Progress Free Survival after administration 2 year post infusion
Secondary Overall survival (OS) overall survival refers to the period from being included in the test group to death caused by any reason 2 years post infusion
See also
  Status Clinical Trial Phase
Suspended NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Not yet recruiting NCT05775146 - SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases Phase 2
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A